IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure

Oncotarget

Volumn 7, Issue 31, 2016, Pages 49027-49041

  Liu, Liang Ming ^a   Tu, Wen Juan ^a   Zhu, Tong ^a   Wang, Xiao Ting ^a   Tan, Zhi Li ^a   Zhong, Huan ^a   Gao, De Yong ^a   Liang, Dong Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acute liver failure; Immune response; Immune mediated inflammation; Immunity; Immunology and Microbiology Section; IRF3; Kupffer cells; Urotensin II

Indexed keywords

BETA INTERFERON; GALACTOSAMINE; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELA; URANTIDE; UROTENSIN II; UROTENSIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; IRF3 PROTEIN, MOUSE; PEPTIDE FRAGMENT; RELA PROTEIN, MOUSE; RELA PROTEIN, RAT; SMALL INTERFERING RNA; UROTENSIN; UROTENSIN II (4-11), PEN(5)-TRP(7)-ORN(8)-; UROTENSIN II RECEPTOR, MOUSE;

ACUTE LIVER FAILURE; ADENOVIRIDAE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; INFLAMMATORY LIVER INJURY; KUPFFER CELL; LIVER INJURY; MALE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; INFLAMMATION; METABOLISM; MOUSE; NUCLEOCYTOPLASMIC TRANSPORT; SPRAGUE DAWLEY RAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ADENOVIRIDAE; ANIMALS; GALACTOSAMINE; INFLAMMATION; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-6; KUPFFER CELLS; LIVER FAILURE, ACUTE; MALE; MICE; MICE, INBRED BALB C; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; UROTENSINS;

EID: 84981309766     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10717     Document Type: Article

References (41)

1. Wu Z, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int, 2010; 30: 782-794.
2. Jiang X, Li Z, Jiang S, Tong X, Zou X, Wang W, Zhang Z, Wu L, Tian D. Lipoxin A4 exerts protective effects against experimental acute liver failure by inhibiting the NF-κB pathway. Int J Mol Med, 2016. doi: 10.3892/ijmm.2016.2483. [Epub ahead of print].
3. Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol, 2010; 298(5): 1156-1172.
4. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Clonning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998; 95(26): 15803-15808.
5. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol, 1999; 1(6): 383-385.
6. Vaudry H, Do Rego JC, Le Mevel JC, Chatenet D, Tostivint H, Fournier A, Tonon MC, Pelletier G, Conlon JM, Leprince J. Urotensin II, from fish to human. Ann N Y Acad Sci, 2010; 1200: 53-66.
7. Desai N, Sajjad J, Frishman WH. Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease. Cardiology in Review, 2008; 16(3): 142-153.
8. Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Blétière D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol, 2007; 179: 901-909.
9. Cirillo P, De Rosa S, Pacileo M, Gargiulo A, Angri V, Fiorentino I, Prevete N, Petrillo G, De Palma R, Leonardi A, De Paulis A, Chiariello M. Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J Thromb Haemost, 2008; 6: 726-736.
10. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol, 2004; 370: 238-250.
11. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides, 2004; 25: 1767-1774.
12. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet, 2002; 359: 1990-1997.
13. Balat A, Karakök M, Yilmaz K, Kibar Y. Urotensin-II immunoreactivity in children with chronic glomerulonephritis. Renal Failure, 2007; 29: 573-578.
14. Liu D, Chen J, Wang J, Zhang Z, Ma X, Jia J, Wang Y. Increased expression of urotensin II and UT in patients with cirrhosis and portal hypertension. Int J Mol Med, 2010; 25: 845-851.
15. Leifeld L, Clemens C, Sauerbruch T, Trebicka J, Sauerbruch T, Spengler U. Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. Dig Dis Sci, 2010; 55(5): 1458-1464.
16. Liang DY, Liu LM, Ye CG, Zhao L, Yu FP, Gao DY, Wang YY, Yang ZW, Wang YY. Inhibition of UII/UTR systen relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice. PloS ONE, 2013; 8(6): e64895.
17. Wheeler MD. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health, 2003; 27(4): 300-306.
18. Borlak J, Langer F, Spanel R, Schöndorfer G, Dittrich C. Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors. Oncotarget, 2016. doi: 10.18632/oncotarget.8574. [Epub ahead of print].
19. Tsutsui H, Nishiguchi S. Importance of Kupffer cells in the development of acute liver injuries in mice. Int J Mol Sci, 2014; 15(5): 7711-7730.
20. Liu LM, Liang DY, Ye CG, Tu WJ, Zhu T. The UII/UT System mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB Pathways in LPS-Stimulated Kupffer Cells. PLoS One, 2015; 10(3): e0121383.
21. Tarassishin L, Bauman A, Suh H S, Lee SC. Anti-viral and anti-inflammatory mechanisms of the innate immune transcription factor interferon regulatory factor 3: relevance to human CNS diseases. J Neuroimmune Pharmacol, 2013; 8: 132-144.
22. Liu H, Chen K, Feng WQ, Guo J, Li H. HSV-2 Increases TLR4-dependent phosphorylated IRFs and IFN-β induction in cervical epithelial cells. PLoS One, 2014; 9: e94806.
23. Roy S, Karmakar M, Pearlman E. CD14 Mediates Tolllike Receptor 4 (TLR4) Endocytosis and Spleen Tyrosine Kinase (Syk) and Interferon Regulatory Transcription Factor 3 (IRF3) Activation in Epithelial Cells and Impairs Neutrophil Infiltration and Pseudomonas aeruginosa Killing in Vivo. J Biol Chem, 2014; 289: 1174-1182.
24. Liehl P, Zuzarte-Luís V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassnig C, Müller M, Kalinke U, Saeed M, Chora AF, Golenbock DT, Strobl B, et al. Host-cell sensors for plasmodium activate innate immunity against liver-stage infection. Nat Med, 2014; 20: 47-53.
25. Rustagi A, Gale Jr M. Innate antiviral immune signaling, viral evasion and modulation by HIV-1. J Mol Biol, 2014; 426: 1161-1177.
26. Liu LM, Zhao L, Liang DY, Yu FP, Ye CG, Tu WJ, Zhu T. Effects of urotensin-II on cytokines in early acute liver failure in mice. World J Gastroenterol, 2015; 21(11): 3239-3244.
27. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology, 2012; 142: 978-988.
28. Yu GY, He G, Li CY, Tang M, Grivennikov S, Tsai WT, Wu MS, Hsu CW, Tsai Y, Wang LH, Karin M. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Mol Cell, 2012; 48: 313-321.
29. Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of tolllike receptor signaling pathway. J Pineal Res, 2011; 50: 403-411.
30. Szabo G, Petrasek J, Bala S. Innate immunity and alcoholic liver disease. Dig Dis, 2012; 30: 55-60.
31. Takeuchi O. IRF3: a molecular switch in pathogen responses. Nat Immunol, 2012; 13(7): 634-635.
32. Black KE, Collins SL, Hagan RS, Hamblin MJ, Chan-Li Y, Hallowell RW, Powell JD, Horton MR. Hyaluronan fragments induce IFNbeta via a novel TLR4-TRIF-TBK1-IRF3-dependent pathway. J Inflamm (Lond), 2013; 10(1): 23-30.
33. Chatenet D, Nguyen T, Letourneau, M. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. Front Endocrinol (Lausanne), 2012; 3(2): 174-182.
34. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, Du F, Ren J, Wu YT, Grishin NV, Chen ZJ. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science, 2015; 347(6227): aaa2630.
35. Zhu M, Fang T, Li S, Meng K, Guo D. Bipartite nuclear localization signal controls nuclear import and DNAbinding activity of IFN. J Immunol, 2015; 195(1): 289-297.
36. Siegfried A, Berchtold S, Manncke B, Deuschle E, Reber J, Ott T, Weber M, Kalinke U, Hofer MJ, Hatesuer B, Schughart K, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Weber F, Hornef MW, Autenrieth IB, Bohn E. IFIT2 is an effector protein of type I IFN-mediated amplification of lipopolysaccharide (LPS)-induced TNF-α secretion and LPS-induced endotoxin shock. J Immunol, 2013; 191(7): 3913-3921.
37. Karaghiosoff MR, Steinborn P, Kovarik G, Kriegshäuser G, Baccarini M, Donabauer B, Reichart U, Kolbe T, Bogdan C, Leanderson T, Levy D, Decker T, Müller M. Central role for type I interferons and Tyk2 in lipopolysaccharideinduced endotoxin shock. Nat Immunol, 2003; 4: 471-477.
38. Huys LF, Van Hauwermeiren L, Dejager E, Dejonckheere E, Lienenklaus S, Weiss S, Leclercq G, Libert C. Type I interferon drives tumor necrosis factor-induced lethal shock. J Exp Med, 2009; 206: 1873-1882.
39. Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol, 2002; 168: 6404-6411.
40. Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology. 2014; 4: 1-15.
41. Krause P, Morris V, Greenbaum JA, Park Y, Bjoerheden U, Mikulski Z, Muffley T, Shui JW, Kim G, Cheroutre H, Liu YC, Peters B, Kronenberg M, Murai M. IL-10-producing intestinal macrophages prevent excessive antibacterial innate immunity by limiting IL-23 synthesis. Nat Commun, 2015; 6: 7055.